-
Germans vote in elections threatening fresh blow to Merz
-
Russians vote on last day of parliamentary elections
-
US fears rapid escalation in Mideast after Houthis attack Riyadh
-
Hong Kong pays final respects to former city leader Tung
-
Japan triathlete Hojo wins first gold of Asian Games
-
Typhoon put people off Asian Games opening ceremony, official says
-
IOC president impressed by 'beautiful' Asian Games wooden huts
-
China's 13-year-old Yu cruises as Asian Games swimming begins
-
First Asian Games gold goes to Japan as China's 13-year-old Yu lights up pool
-
AI 'warning shots' focus Beijing on national security risks
-
Data centre command hub keeps AI up and running
-
Philippine tribe in limbo over US-led tech hub
-
Pope Leo in France: the issues on the table
-
Leo XIV, first US pope transcends his restrained style
-
Packing for a pope: behind the scenes on foreign trips
-
Singer Ed Sheeran says Gaza situation 'unjustifiable' following controversy
-
Republicans find transgender issues a powerful political weapon in midterm campaigning
-
In 'Tenzing', a Sherpa mountaineer gets his due
-
German state elections threaten new shock waves for Merz
-
Ed Sheeran set to return to stage after Palestinian controversy
-
Chile's Bachelet quits race to be next UN chief
-
Toulouse edge Vannes, Lyon beat Pau to take Top 14 summit
-
Raphinha treble fires perfect Barca to win at Sevilla
-
Germans arrested for Louvre stunt in Mona Lisa hall
-
Thiam makes winning heptathlon return at Decastar meet
-
Saudi-led coalition says Houthis fired ballistic missile at Riyadh
-
Czechs beat USA to qualify for Davis Cup finals
-
France's debt climbs to highest since 1978: ministry
-
Dortmund sink Stuttgart to climb to Bundesliga summit
-
McIlroy two shots off the lead at Wentworth after eagle on 18
-
Trump says will not tolerate attempts to slow AI growth
-
Martinez brace saves Inter in Serie A top-two clash with Roma
-
'It has to stop': runners protest women's murders in S.Africa district
-
Rosenior abused but guides Paris FC past old club Strasbourg
-
Fire erupts near Riyadh airport as Houthis claim strikes
-
Seven-try Lyon beat Pau, climb to Top 14 summit
-
Cuba works to restore power after another blackout
-
Brighton defeat a 'big lesson' against complacency for Arsenal, says Arteta
-
England thrash Sri Lanka again to return to top of T20 rankings
-
Thousands protest inaction over climate crisis in Switzerland
-
Arsenal thrashed by Brighton, sorry Spurs lose again
-
Carapaz out of cycling world championships
-
South Korea, Austria qualify for Davis Cup finals
-
'Fragile' Tottenham beaten by Aston Villa despite late rally
-
Seare shocks Ingebrigtsen to win world 5km gold
-
Mourinho hails Real Madrid grit before Atletico derby clash
-
Brigitte Bardot widower slams sale of star's belongings
-
Martin wins Austrian MotoGP sprint after Acosta crash
-
Aston Villa compound Tottenham's misery despite late rally
-
Japan edge Fiji to win Pacific Nations Cup
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
P.Sousa--PC